{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["In H"],"funding":["NCATS","NCATS NIH HHS","NIH"],"pagination":["1426-1432"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9268394"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(7)"],"pubmed_abstract":["Background
Gastric cancer lacks specific symptoms, resulting in diagnosis at later stages and high mortality. Serum pepsinogen is a biomarker for atrophic gastritis, a gastric cancer precursor, and may be useful to detect persons at increased risk of gastric cancer.Methods
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial was conducted in the United States between 1993 and 2001. ELISA-based pepsinogen tests were conducted on prediagnostic serum samples of 105 PLCO participants who developed gastric cancer and 209 age, sex, and race-matched controls. Pepsinogen positive (PG+) was defined as pepsinogen I ≤ 70 μg/L and pepsinogen I/II ratio ≤3.0. Results of conditional logistic regression models, and sensitivity and specificity, of PG+ for gastric cancer"],"journal":["Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"],"pubmed_title":["Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data."],"pmcid":["PMC9268394"],"funding_grant_id":["5UL1TR002556–05","UL1 TR002556"],"pubmed_authors":["Yang J","Sarkar S","Ward J","Epplein M","In H","Friedmann P","Parides M"],"additional_accession":[]},"is_claimable":false,"name":"Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data.","description":"Background
Gastric cancer lacks specific symptoms, resulting in diagnosis at later stages and high mortality. Serum pepsinogen is a biomarker for atrophic gastritis, a gastric cancer precursor, and may be useful to detect persons at increased risk of gastric cancer.Methods
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial was conducted in the United States between 1993 and 2001. ELISA-based pepsinogen tests were conducted on prediagnostic serum samples of 105 PLCO participants who developed gastric cancer and 209 age, sex, and race-matched controls. Pepsinogen positive (PG+) was defined as pepsinogen I ≤ 70 μg/L and pepsinogen I/II ratio ≤3.0. Results of conditional logistic regression models, and sensitivity and specificity, of PG+ for gastric cancer","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-19T18:09:28.991Z","creation":"2025-04-19T18:09:28.991Z"},"accession":"S-EPMC9268394","cross_references":{"pubmed":["35534235"],"doi":["10.1158/1055-9965.EPI-21-1328","10.1158/1055-9965.epi-21-1328"]}}